(Q36024673)

English

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response (English)

1 reference

Europe PubMed Central

11 August 2017

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

D R Mould

1

1 reference

Europe PubMed Central

11 August 2017

A Baumann

2

1 reference

Europe PubMed Central

11 August 2017

J Kuhlmann

3

1 reference

Europe PubMed Central

11 August 2017

M J Keating

4

1 reference

Europe PubMed Central

11 August 2017

S Weitman

5

1 reference

Europe PubMed Central

11 August 2017

P Hillmen

6

1 reference

Europe PubMed Central

11 August 2017

L R Brettman

7

1 reference

Europe PubMed Central

11 August 2017

S Reif

8

1 reference

Europe PubMed Central

11 August 2017

P L Bonate

9

1 reference

Europe PubMed Central

11 August 2017

language of work or name

0 references

publication date

16 May 2007

1 reference

Europe PubMed Central

11 August 2017

British Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

11 August 2017

64

1 reference

Europe PubMed Central

11 August 2017

278-291

1 reference

Europe PubMed Central

11 August 2017

3

1 reference

Europe PubMed Central

11 August 2017

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

Pharmacokinetics of CAMPATH-1H: assay development and validation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

Comparison of four basic models of indirect pharmacodynamic responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2000651

2 October 2017

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02914.X

21 January 2018

Assessment of actual significance levels for covariate effects in NONMEM.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02914.X

21 January 2018

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02914.X

21 January 2018

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02914.X

21 January 2018

Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02914.X

21 January 2018

Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2007.02914.X

21 January 2018

Physiologic indirect response models characterize diverse types of pharmacodynamic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/17506867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CAMPATH-1H in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17506867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena

1 reference

https://pubmed.ncbi.nlm.nih.gov/17506867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17506867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/17506867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of CAMPATH-1H in BMT patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17506867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

1 reference

https://pubmed.ncbi.nlm.nih.gov/17506867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2125.2007.02914.X

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36024673&oldid=2143914631"